###begin article-title 0
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLRN1</italic>
Disease-causing mutations in the CLRN1 gene alter normal CLRN1 protein trafficking to the plasma membrane
###end article-title 0
###begin p 1
The first two authors contributed equally to this work.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLRN1</italic>
###xml 328 336 <span type="species:ncbi:9606">patients</span>
Mutations of clarin 1 (CLRN1) cause Usher syndrome type 3 (USH3). To determine the effects of USH3 mutations on CLRN1 function, we examined the cellular distribution and stability of both normal and mutant CLRN1 in vitro. We also searched for novel disease-causing mutations in a cohort of 59 unrelated Canadian and Finnish USH patients.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 106 111 106 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLRN1</italic>
Mutation screening was performed by DNA sequencing. For the functional studies, wild-type (WT) and mutant CLRN1 genes were expressed as hemagglutinin (HA) tagged fusion proteins by transient transfection of BHK-21 cells. Subcellular localization of CLRN1-HA was examined by confocal microscopy. The N-glycosylation status of CLRN1 was studied by using the N-glycosidase F (PNGase F) enzyme and western blotting. Cycloheximide treatment was used to assess the stability of CLRN1 protein.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 146 154 <span type="species:ncbi:9606">patients</span>
We found three previously reported pathogenic mutations, p.A123D, p.N48K, and p.Y176X, and a novel sequence variant, p.L54P, from the studied USH patients. The WT HA-tagged CLRN1 was correctly trafficked to the plasma membrane, whereas mutant CLRN1-HA proteins were mislocalized and retained in the endoplasmic reticulum. PNGase F treatment of CLRN1-HA resulted in an electrophoretic mobility shift consistent with sugar residue cleavage in WT and in all CLRN1 mutants except in p.N48K mutated CLRN1, in which the mutation abolishes the glycosylation site. Inhibition of protein expression with cycloheximide indicated that WT CLRN1-HA remained stable. In contrast, the CLRN1 mutants showed reduced stability.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
WT CLRN1 is a glycoprotein localized to the plasma membrane in transfected BHK-21 cells. Mutant CLRN1 proteins are mislocalized. We suggest that part of the pathogenesis of USH3 may be associated with defective intracellular trafficking as well as decreased stability of mutant CLRN1 proteins.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 188 189 188 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 190 191 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 365 366 365 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 596 597 596 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 780 781 780 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 782 783 782 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 1094 1095 1094 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 1175 1176 1175 1176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 1245 1246 1245 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 1363 1365 1363 1365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 1366 1368 1366 1368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 1487 1488 1487 1488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 1103 1111 <span type="species:ncbi:9606">patients</span>
Usher syndrome (USH) describes a group of autosomal recessive diseases with bilateral sensorineural hearing loss and visual impairment phenotypically similar to retinitis pigmentosa (RP) [1-4]. Prevalence of USH in different populations is estimated to range from 3.5 to 6.2 per 100,000, thus making it the most frequent cause of combined deaf-blindness worldwide [5]. The condition has been classified into three clinical subtypes (USH1, USH2, and USH3), based on the severity and progression of the hearing impairment, presence or absence of vestibular dysfunction, and the age of onset of RP [1]. This classification remains in clinical use, although recent progress on the molecular genetics and clinical research of USH has revealed broad genetic and clinical heterogeneity [3,6]. Atypical forms of USH have been identified within all three clinical types, and there is considerable overlap of symptoms among the subtypes. A distinguishing feature of USH3 is the wide spectrum of nonlinear progressive hearing impairment, which ranges from a near normal to a severe audiometric phenotype [7]. USH3 patients may also have either normal or decreased vestibular responses [8]. The rate of visual loss in USH3 is similar to other USH subtypes [9], with the most recent analyses suggesting that retinal degeneration in USH3 progresses more rapidly than in USH2A [10,11]. The variable phenotype may cause USH3 to be under-diagnosed and it may be more prevalent than previously indicated [6].
###end p 11
###begin p 12
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 496 498 496 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 691 692 691 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 693 694 693 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 695 697 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 698 700 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
To date, nine USH gene products have been identified: the molecular motor myosin VIIa (USH1B) [12]; the cell adhesion proteins cadherin 23 (USH1D) [13] and protocadherin 15 (USH1F) [14,15]; the scaffold proteins harmonin (USH1C) [16], SANS (USH1G) [17], and whirlin (USH2D) [18]; the G-protein-coupled 7-transmembrane receptor VLGR1b (USH2C) [19]; two isoforms of the extracellular matrix connected protein usherin (USH2A) [20,21]; and the four-pass transmembrane domain protein clarin 1 (USH3) [22,23]. There is growing evidence suggesting that these proteins form a network, which is critical for the development and maintenance of the sensorineural cells in the inner ear and the retina [3,4,24-28].
###end p 12
###begin p 13
###xml 66 68 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 128 133 128 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLRN1</italic>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 299 304 299 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLRN1</italic>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 429 434 429 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Clrn1</italic>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 1026 1028 1026 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 1206 1208 1206 1208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 1413 1415 1413 1415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 1471 1476 1471 1476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Clrn1</italic>
###xml 1545 1547 1545 1547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 1548 1550 1548 1550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 1748 1750 1748 1750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 449 454 <span type="species:ncbi:10090">mouse</span>
###xml 593 598 <span type="species:ncbi:10090">mouse</span>
###xml 776 781 <span type="species:ncbi:10090">mouse</span>
###xml 1486 1491 <span type="species:ncbi:10090">mouse</span>
###xml 1556 1561 <span type="species:ncbi:10090">mouse</span>
Since the original identification of the causative gene for USH3 [22], the gene's structure has been refined. The newly defined CLRN1 has three exons, encoding a 232 amino acid protein [23,29]. Northern blot and reverse-transcription PCR analyses indicate expression of different splice variants of CLRN1 mRNA in several tissues including retina, cochlea, brain, and thymus [22,23,29]. In situ hybridization analyses demonstrate Clrn1 expression in mouse cochlear hair cells and spiral ganglion cells as early as embryonic day (E) 16.5 [23,30]. The CLRN1 protein is thought to be expressed in mouse cochlea transiently from E18 to postnatal day (P) 6 in basal parts of the hair cells, whereas in apical parts (stereocilia) the CLRN1 expression is lost already at P1. In adult mouse retina CLRN1 localizes to inner segments, connecting cilia and ribbon synapses. The function of CLRN1 remains unknown; however, the spatiotemporal expression pattern of CLRN1 in hair cells implicates protein involvement in synaptic maturation [31]. Structural and sequence homology with the synaptic protein stargazin suggest a role for CLRN1 in the plasma membranes surrounding ribbon synapses of the inner ear and retina [23]. In cell culture studies CLRN1 forms microdomains in the plasma membrane, affects F-actin organization and induces lamellipodia formation, implicating CLRN1 involvement in actin cytoskeleton regulation [28]. This hypothesis is supported by the observation that Clrn1 knockout mouse F-actin-rich hair cell stereocilia are disorganized [28,30]. In mouse hair cell cultures, however, CLRN1 associates with tubulin and not with actin, and localizes to post-transgolgi vesicles, suggesting a potential function for CLRN1 in vesicle transport [31].
###end p 13
###begin p 14
###xml 314 315 314 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 596 598 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 1229 1230 1229 1230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 1231 1233 1231 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 1234 1236 1234 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 1237 1239 1237 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 1240 1242 1240 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 1243 1245 1243 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 1246 1248 1246 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 1249 1251 1249 1251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 799 807 <span type="species:ncbi:9606">patients</span>
###xml 891 899 <span type="species:ncbi:9606">patients</span>
###xml 949 956 <span type="species:ncbi:9606">patient</span>
###xml 1007 1014 <span type="species:ncbi:9606">patient</span>
###xml 1080 1088 <span type="species:ncbi:9606">patients</span>
###xml 1161 1169 <span type="species:ncbi:9606">patients</span>
To date, USH3 has been described as the rarest of the USH types worldwide. The availability of molecular diagnosis is increasing the number of USH3 cases identified. Interestingly, in unrelated Ashkenazi Jewish and Finnish populations, USH3 comprises 40% of all the USH cases, suggesting multiple founder effects [9,32]. Among Ashkenazi Jews of European and North American descent, a c.144T>G mutation is causative of the majority of the USH3 cases. This mutation causes a substitution of asparagine to lysine (p.N48K), and removes the single N-glycosylation consensus site on the CLRN1 protein [29]. The most common mutation in Finland is c.528T>G, which is predicted to generate a premature termination of the CLRN1 polypeptide (p.Y176X). Eleven other CLRN1 mutations have been documented in USH3 patients around the world. These mutations include c.359T>A (p.M120K) found in four Finnish patients, c.368C>A (p.A123D) found in one French Canadian patient, c.449T>C (p.L150P) found in one Ashkenazi Jewish patient, and c.459_461del (p.I153_L154delinsM) identified in two Italian patients. The other seven known CLRN1 mutations have been found in either single patients or isolated families with predominantly European ancestry [8,11,18,22,23,29,32-34].
###end p 14
###begin p 15
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLRN1</italic>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
In this study, we sequenced the coding region of CLRN1 in 59 USH patients who had no known disease-causing mutations. Furthermore, we examined intracellular targeting, stability, and N-glycosylation of the aforementioned mutants in addition to WT CLRN1 using a transient transfection assay in BHK-21 cells.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
Subjects
###end title 17
###begin p 18
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 103 111 <span type="species:ncbi:9606">Children</span>
Patients diagnosed with USH were recruited through the Ocular Genetics Clinic at The Hospital for Sick Children in Toronto, Ontario, Canada and from Helsinki University Eye Hospital, Helsinki, Finland. This study followed the tenets of the Declaration of Helsinki.
###end p 18
###begin title 19
Clinical examinations
###end title 19
###begin p 20
The diagnosis of USH was based on comprehensive ophthalmological and audiological examinations including Snellen visual acuity, biomicroscopy and fundus examinations, Goldmann visual field tests, electroretinograms, and pure tone audiograms. When possible, optical coherent tomography (OCT) was performed.
###end p 20
###begin title 21
Mutation analysis
###end title 21
###begin p 22
###xml 156 161 156 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLRN1</italic>
###xml 689 694 671 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLRN1</italic>
###xml 1644 1649 1588 1593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLRN1</italic>
###xml 41 49 <span type="species:ncbi:9606">patients</span>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 187 195 <span type="species:ncbi:9606">Patients</span>
###xml 603 610 <span type="species:ncbi:9606">patient</span>
DNA samples of 40 unrelated Canadian USH patients without previously known mutations and 19 USH patients diagnosed in Finland after 2001 were sequenced for CLRN1 mutation identification. Patients' genomic DNA was extracted either from fresh or frozen whole blood samples with Puregenetrade mark Genomic DNA Purification Kit (Gentra Systems, MN) or from saliva with Oragenetrade mark kits (DNA Genotek Inc., Ontario, Canada). A total of 90 Centre d'Etude du Polymorphisme Humain () samples were used as controls for assessing the pathogenicity of the novel change found in this study from a Canadian USH patient. The three exons and the exon-intron boundaries of the main splice variant of CLRN1 gene (GenBank accession ) were screened for mutations by genomic sequencing. The primers used for sequencing were: exon 0 sense 5'-CAG AAA AGG AGA AAA GCC AAG-3'; exon 0 antisense 5'-CTG GGA AGA GTC TGC CTA AA-3'; exon 2 sense 5'-TCA GAA GGA TTT TAG TGA TGT TTG A-3'; exon 2 antisense 5'-TCT TTT TGA CAT ATT GAA AAG CAC A-3'; exon 3 sense 5'-CCC TCT TCC CTG TCC CTT AC -3'; exon 3 antisense 5'- CCA CAT CTA AAA GTG ACC AAA GC-3'. The amplification conditions were 95 degreesC for 5 min (denaturation), then 30 cycles of 95 degreesC for 45 s, 60 degreesC (exon 2) or 55 degreesC (exons 0 and 3) for 45 s, 72 degreesC for 45 s, followed by a final extension of 10 min at 72 degreesC. PCR products were purified with Exo-SAP (USB, Cleveland, OH) and then sequenced with an ABI2720 Automatic DNA sequencer using the ABI PRISM BigDye(R) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA). The sequences were compared to the known CLRN1 main splice variant sequence ().
###end p 22
###begin title 23
Construction of expression plasmids
###end title 23
###begin p 24
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLRN1</italic>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
Wild-type (WT) CLRN1 construct was cloned into the phCMV3 Xi cloning vector (Gene Therapy Systems, Inc., San Diego, CA) with C-terminal hemagglutinin epitope YPYDVPDYA (HA-tag) from the influenza virus A as recently described [28]. The mutant cDNA constructs representing mutations/sequence alterations p.N48K, p.L54P, p.M120K, p.A123D, p.L150P, and p.I153_L154delinsM were generated by the QuikChange site-directed in vitro mutagenesis kit, according to the manufacturer's protocols (Stratagene, La Jolla, CA). All coding regions of the constructs were sequence verified.
###end p 24
###begin title 25
Cell culture and transfections
###end title 25
###begin p 26
###xml 565 566 529 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 143 147 <span type="species:ncbi:9913">calf</span>
BHK-21 cells (CCL-10, ATCC) were cultured in Glasgow minimal essential medium (GMEM, Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal calf serum (FCS; PromoCelltrade mark, Heidelberg, Germany), Gibcotrade mark GlutaMAXtrade mark supplement (100x, L-alanyl-L-glutamine, Invitrogen), 5% tryptose phosphate broth solution (Sigma-Aldrich), and penicillin-streptomycin (100x, Sigma-Aldrich, Germany). For transfection, cells were seeded on 13 mm coverslips (Menzel-Glaser, Braunschweig, Germany) in six well plates (Nunctrade mark, Denmark) at a density of 2x105 cells per well 20 h before transfection. Transfection was performed with the FuGENE 6 Transfection Reagent (Roche Diagnostics, Indianapolis, IN) following the guidelines supplied by the manufacturer. Experiments were performed 24 or 48 h post transfection.
###end p 26
###begin title 27
Immunofluorescence imaging
###end title 27
###begin p 28
###xml 468 469 464 465 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 472 473 468 469 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 488 489 484 485 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 491 492 487 488 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 537 543 <span type="species:ncbi:9913">bovine</span>
WT and mutant CLRN1-HA transfected cells were fixed with 4% paraformaldehyde (PFA; pH 7.5) for 15 min before immunofluorescence staining. For stability analyses, protein synthesis was stopped by adding 50 microg/ml cycloheximide (Sigma-Aldrich) and incubating BHK-21 cells in it before fixation (as above). After fixation, BHK-21 cells were permeabilized for 20 min with 0.2% saponin (Sigma-Aldrich) in phosphate buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 1.5 mM KH2PO4 in distilled water, pH 7.4) containing 0.5% bovine serum albumin (BSA; Sigma-Aldrich). Thereafter, the cells were incubated for 45 min with a 1:700 dilution of monoclonal anti-HA antibody (HA.11, MMS-101R; Covance, Berkeley, CA) and either with a 1:50 dilution of plasma membrane antibody to sodium potassium ATPase (ab7671; Abcam, Cambridge, UK), or a 1:200 dilution of an ER antibody to protein disulfide isomerase (PDI, spa-891; Stressgen, Victoria, Canada). Cy2- and Cy3-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA) were used to visualize the primary antibodies. The cells were mounted with Gel/Mount (Biomeda, Foster City, CA) and analyzed with a Leica DMR confocal microscope with TCS NT software, or a Zeiss Axioplan 2 microscope with AxioVision 3.1 software.
###end p 28
###begin title 29
Western blot and deglycosylation analyses
###end title 29
###begin p 30
###xml 1003 1009 <span type="species:ncbi:9986">rabbit</span>
###xml 1015 1020 <span type="species:ncbi:10090">mouse</span>
Transfected BHK-21 cells were harvested from six-well plates for western blot analysis by scraping in ice-cold PBS supplemented with protease inhibitors (Complete; Roche Diagnostics). Cells were collected by centrifugation. These were lysed with 200 microl glycoprotein denaturing buffer (0.5% SDS, 40 mM DTT; New England Biolabs, Ipswich, MA). Cells were further homogenized by passage through a 21 gauge needle. Next, 2 microl of 10% NP-40 and 2 microl of 50 mM sodium phosphate buffer, pH 7.5 (G7 Reaction Buffer) was added to the 15 microl sample of the cell homogenate. Samples for deglycosylation studies were treated with 0.5 microl (500 units/microl) of N-glycosidase F (PNGase F; New England Biolabs) enzyme for 2 h at 37 degreesC. Samples were separated on a 12% SDS-PAGE gel and transferred to a Trans-Blot(R) nitrocellulose membrane (Bio-Rad, Hercules, CA). The membrane was immunostained with a 1:1,000 dilution of monoclonal anti-HA antibody (Covance) and a 1:1,000 dilution of polyclonal rabbit anti-mouse IgG conjugated to HRP (DakoCytomation, Glostrup, Denmark). Bands were visualized by SuperSignal(R) West Pico Chemiluminescent Substrate (Pierce, Rockford, IL) and captured on X-ray film (Kodak Biomax MR Film, Sigma-Aldrich).
###end p 30
###begin title 31
Bioinformatics
###end title 31
###begin p 32
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
The theoretical molecular weights of CLRN1-HA polypeptides were calculated with the  [35]. The  program was used for prediction of membrane spanning regions [36].
###end p 32
###begin title 33
Results
###end title 33
###begin title 34
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLRN1</italic>
Sequence alterations in CLRN1
###end title 34
###begin p 35
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLRN1</italic>
###xml 124 129 124 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLRN1</italic>
###xml 276 281 276 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLRN1</italic>
###xml 381 389 381 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 690 698 690 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 772 774 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 1181 1186 1181 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLRN1</italic>
###xml 1254 1261 1254 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 1324 1329 1324 1329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLRN1</italic>
###xml 1343 1351 1343 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
###xml 310 317 <span type="species:ncbi:9606">patient</span>
###xml 572 579 <span type="species:ncbi:9606">patient</span>
###xml 763 770 <span type="species:ncbi:9606">patient</span>
###xml 913 921 <span type="species:ncbi:9606">patients</span>
###xml 1006 1013 <span type="species:ncbi:9606">patient</span>
###xml 1051 1058 <span type="species:ncbi:9606">patient</span>
###xml 1227 1235 <span type="species:ncbi:9606">patients</span>
The sequencing of the CLRN1 coding region from the 40 Canadian USH patients revealed two previously published and one novel CLRN1 sequence alteration. The previously unreported c.161T>C transition, found in heterozygous form, predicts a p.L54P change. We did not find another CLRN1 sequence alteration in this patient, but the changed amino acid leucine is conserved in evolution (Figure 1). Thus, the pathogenic nature of this alteration was investigated further. A transition mutation c.368C>A predicting a p.A123D change was identified in homozygous form in a Canadian patient originating from Dominica. The mutation changes another highly conserved amino acid alanine to aspartic acid (Figure 1). This change has previously been reported in a French Canadian patient [34] and is very likely a mutation causing USH3. Neither c.161T>C nor c.368C>A were found from the 90 CEPH control samples nor the 19 Finnish patients we sequenced. The Ashkenazi Jewish mutation (p.N48K) was detected in a Canadian USH patient in homozygous form, and in a Finnish patient in heterozygous form with the Finnish founder mutation p.Y176X. The mutations identified in the present study, as well as CLRN1 disease-causing mutations identified in patients in other studies (Table 1), are summarized on a schematic presentation of the predicted CLRN1 structure in Figure 2.
###end p 35
###begin p 36
###xml 210 222 210 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Homo sapiens</italic>
###xml 229 244 229 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pan troglodytes</italic>
###xml 251 261 251 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bos taurus</italic>
###xml 268 280 268 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mus musculus</italic>
###xml 287 300 287 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gallus gallus</italic>
###xml 307 318 307 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Danio rerio</italic>
###xml 210 222 <span type="species:ncbi:9606">Homo sapiens</span>
###xml 229 244 <span type="species:ncbi:9598">Pan troglodytes</span>
###xml 251 261 <span type="species:ncbi:9913">Bos taurus</span>
###xml 268 280 <span type="species:ncbi:10090">Mus musculus</span>
###xml 287 300 <span type="species:ncbi:9031">Gallus gallus</span>
###xml 307 318 <span type="species:ncbi:7955">Danio rerio</span>
Sequence conservation around the p.L54P and p.A123D changes. Amino acids conserved in evolution are marked in bold, and mutations are marked with red. Mutations are also marked with an asterisk. Abbreviations: Homo sapiens (HS), Pan troglodytes (Pt), Bos taurus (Bt), Mus musculus (Mm), Gallus gallus (Gg), Danio rerio (Dr).
###end p 36
###begin title 37
CLRN1 mutations and their prevalences.
###end title 37
###begin p 38
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
Disease-causing USH3 mutations identified in patients are listed with the number of patients and families reported to be affected by these mutations.
###end p 38
###begin p 39
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
Predicted membrane topology of CLRN1. Disease-associated mutations are marked; the frameshift and nonsense mutations are marked with red amino acids, missense mutations are marked with blue amino acids, and the deleted amino acids replaced by an insertion are marked with green. Transmembrane regions (1-4) were predicted using a TMHMM2.0 program [36]. The mutations studied in this article are marked with red.
###end p 39
###begin title 40
###xml 25 33 <span type="species:ncbi:9606">patients</span>
Clinical findings in the patients whose mutations were found in this study
###end title 40
###begin p 41
###xml 393 402 393 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3D</xref>
###xml 876 885 876 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3C</xref>
###xml 1437 1446 1437 1446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3B</xref>
###xml 13 20 <span type="species:ncbi:9606">patient</span>
###xml 418 425 <span type="species:ncbi:9606">patient</span>
###xml 989 996 <span type="species:ncbi:9606">patient</span>
The Canadian patient with a homozygous p.N48K mutation was diagnosed with RP and hearing loss in his late teens. At age 54, he had 5 degree visual fields with the III4e stimulus. His best-corrected visual acuities were 20/30 OU (following cataract surgery). He had a mild to moderate, downsloping sensorineural hearing loss and poor balance. OCT showed small cystic macular changes at age 52 (Figure 3D). The Canadian patient with the homozygous p.A123D mutation had progressive sensorineural hearing loss that was first noted at age 7. By age 32, her hearing loss was moderately severe, sloping to profound hearing loss. She noticed symptoms of RP at age 25, when her ERG was nonrecordable. At 36, her visual fields were 12 degrees measured with the III4e stimulus, and the best-corrected visual acuities were 20/25 OU. On OCT, there was a schisis-like change in her macula (Figure 3C). Fundus changes were otherwise characteristic of RP. The Finnish p.N48K/p.Y176X compound heterozygous patient was diagnosed with sensorineural hearing loss at age 7; testing revealed a U-shaped audiogram. At age 8, his visual acuity was 20/20 OU. He had slight mottling of the pigment in his peripheral fundi, and his visual fields, measured with the V4e standard light, were normal. His full-field ERGs were nonrecordable. On OCT examination, the foveal thickness looked fairly normal but there was thinning of the retina outside the central fovea (Figure 3B).
###end p 41
###begin p 42
###xml 74 75 74 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 139 140 139 140 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 302 303 302 303 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 445 446 445 446 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 158 165 <span type="species:ncbi:9606">patient</span>
###xml 284 291 <span type="species:ncbi:9606">patient</span>
###xml 322 329 <span type="species:ncbi:9606">patient</span>
###xml 427 434 <span type="species:ncbi:9606">patient</span>
###xml 465 472 <span type="species:ncbi:9606">patient</span>
Optical coherence tomographs of a normal control and three USH3 patients. A: 32-year-old healthy control with visual acuity (VA) of 20/20. B: 8-year-old USH3 patient with heterozygous p.Y176X and p.N48K mutations and VA of 20/20. The arrow points to the region of retinal thinning in patient's macula. C: 35-year-old USH3 patient with homozygous p.A123D mutation and VA of 20/25. The arrow points to the schisis-like change in patient's macula. D: 52-year-old USH3 patient with homozygous p.N48K mutation and VA of 20/30. The arrow points to the intraretinal cysts. Scale bar represents 1 mm.
###end p 42
###begin title 43
Cellular localization of CLRN1-HA
###end title 43
###begin p 44
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLRN1</italic>
###xml 594 605 594 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4A-C</xref>
###xml 670 681 670 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4D-F</xref>
###xml 945 953 945 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5</xref>
###xml 1027 1038 1027 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f6">Figure 6A-C</xref>
###xml 1061 1072 1061 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f6">Figure 6D-F</xref>
###xml 1113 1124 1113 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f6">Figure 6G-I</xref>
###xml 1189 1196 <span type="species:ncbi:9606">patient</span>
To determine the cellular localization of the CLRN1 protein, we cloned the transcript of CLRN1 () into a HA-tagged phCMV mammalian expression vector. We generated mutant cDNA constructs by the QuikChange site-directed mutagenesis kit. The mutant and WT proteins were transiently expressed in BHK-21 cells. Their refined cellular localizations were visualized by anti-HA, anti-ER (protein disulfide isomerase), and anti-plasma membrane (sodium potassium ATPase) antibodies, using confocal immunofluorescence microscopy. WT CLRN1 was observed throughout the plasma membrane of transfected cells (Figure 4A-C), but it also showed partial colocalization with the ER marker (Figure 4D-F), indicating its normal processing through the ER to the plasma membrane. In contrast, all known mutant proteins analyzed colocalized almost exclusively within the ER, suggesting that they are retained therein and prevented from targeting to the plasma membrane (Figure 5). The novel sequence alteration p.L54P localized to the plasma membrane (Figure 6A-C) similar to WT CLRN1 (Figure 6D-F), and unlike the known mutation p.N48K (Figure 6G-I). The biologic significance of the p.L54P alteration found in a patient in heterozygous form remains thus unclear.
###end p 44
###begin p 45
###xml 84 85 84 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 90 91 90 91 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 154 155 154 155 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 247 248 247 248 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 307 308 307 308 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 313 314 313 314 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
Cellular localization of WT CLRN1-HA protein in transfected BHK-21 cells. In panels B and E the cells were immunostained with HA antibody (red). In panel A the cells were immunostained with a plasma membrane specific antibody (green) and in panel D with ER specific antibody (green). The right-most panels (C and F) show the overlay of both CLRN1-HA and the organelle-specific double staining. Yellow-orange staining indicates an overlap of the CLRN1-HA protein (red) and subcellular markers (green). Cells were viewed with a confocal immunofluorescence microscope, magnification 63x. Scale bar represents 10 mum.
###end p 45
###begin p 46
###xml 163 164 163 164 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 166 167 166 167 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 169 170 169 170 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</bold>
###xml 172 173 172 173 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</bold>
###xml 179 180 179 180 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</bold>
###xml 236 237 236 237 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 239 240 239 240 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 242 243 242 243 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 245 246 245 246 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">J</bold>
###xml 252 253 252 253 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</bold>
###xml 327 328 327 328 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 330 331 330 331 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 333 334 333 334 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</bold>
###xml 336 337 336 337 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</bold>
###xml 343 344 343 344 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</bold>
Cellular localization of the disease-causing mutant CLRN1-HA polypeptides. The transfected BHK-21 cells were double immunostained with HA antibody (red) in panels B, E, H, K, and N showing the localization of mutant CLRN1-HA. In panels A, D, G, J, and M the cells were stained with the ER marker (green). The right-most panels C, F, I, L, and O show the overlay of the mutant CLRN1- HA staining (red) and ER-specific staining (green). Yellow-orange staining indicates colocalization of these stainings. Cells were viewed with a confocal immunofluorescence microscope. Scale bar represents 10 microm.
###end p 46
###begin p 47
###xml 186 187 186 187 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 245 246 245 246 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 303 304 303 304 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</bold>
###xml 399 400 399 400 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 402 403 402 403 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 409 410 409 410 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 452 453 452 453 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 488 489 488 489 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 578 579 578 579 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</bold>
Cellular localization of the p.L54P, p.N48K and WT CLRN1-HA polypeptides. The transfected BHK-21 cells were immunostained with HA antibody (red) showing the localization of WT CLRN1-HA (E), the novel sequence alteration p.L54P mutated CLRN1-HA (B) and the known disease-causing p.N48K mutated CLRN1-HA (H). The same cells were immunostained with plasma membrane -specific antibody (green) in panels A, D, and G. Double-staining shows that WT CLRN1-HA (F) and the p.L54P mutated CLRN1-HA (C) colocalize (yellow) with the plasma membrane marker whereas the known mutation p.N48K (I) does not colocalize with the plasma membrane marker. Cells were viewed with a confocal immunofluorescence microscope. Scale bar represents 10 microm.
###end p 47
###begin title 48
Stability of WT and mutant CLRN1-HA polypeptides
###end title 48
###begin p 49
###xml 359 367 359 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f7">Figure 7</xref>
We studied the stability of the WT and mutant CLRN1-HA proteins by interrupting protein synthesis in transfected BHK-21 cells by cycloheximide treatment and examining how much protein remained after 4 h. WT CLRN1, the p.I153_L154delinsM and p.M120K mutants could still be detected, while the p.N48K, p.A123D and p.L150P mutants were almost completely absent (Figure 7). ER marker served as a control. Stability of the marker was unaltered by cycloheximide treatment (data not shown).
###end p 49
###begin p 50
Stability of WT and mutant CLRN1-HA polypeptides in transfected BHK-21 cells. Cells were transiently transfected either with WT or mutant CLRN1-HA cDNAs. At 48 h posttransfection protein synthesis was stopped by incubating the cells for 4 h in the presence of 50 microg/ml of cycloheximide. Cells were viewed with a Zeiss Axioplan 2 fluorescence microscope. The scale bar represents 50 microm.
###end p 50
###begin title 51
CLRN1-HA forms multimers
###end title 51
###begin p 52
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 521 529 521 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f8">Figure 8</xref>
###xml 618 626 618 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f8">Figure 8</xref>
###xml 798 806 798 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f8">Figure 8</xref>
###xml 979 981 979 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 1164 1172 1164 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f8">Figure 8</xref>
Based on , the molecular weight of WT CLRN1-HA with no modifications is 26.81 kDa [35]. WT CLRN1-HA has a single putative N-glycosylation site at amino acid position 48 [23,28]. To study CLRN1 glycosylation in vitro, we treated HA-tagged WT CLRN1 and p.N48K mutated CLRN1 polypeptides produced in transiently transfected BHK-21 cells with PNGase F, an enzyme that removes all N-linked oligosaccharide side chains from glycoproteins. Western blot analysis of WT CLRN1-HA showed several bands ranging from 23 up to 98 kDa (Figure 8, lane 1). After PNGase F treatment, two major bands at 27 kDa and 48 kDa were observed (Figure 8, lane 2). In contrast, PNGase F treatment had no effect on p.N48K samples: the same 23, 27, and 48 kDa bands were observed in both PNGase F treated and untreated samples (Figure 8, lanes 3 and 4). These results confirm that CLRN1 is a glycoprotein like previously reported and that the p.N48K mutation disrupts the protein's single glycosylation site [28]. The presence of a 48 kDa band suggests that CLRN1 has a tendency to form dimers. The other studied mutations, p.M120K, p.A123D, p.L150P, and p.I153_L154delinsM, were glycosylated (Figure 8, lanes 7-16), and clearly showed decreased molecular weights following PNGase F treatment. Their glycoform patterns were, however, different from that of the WT, probably reflecting their retention in the ER.
###end p 52
###begin p 53
Western blot analysis of the wild-type and mutant CLRN1-HA polypeptides. BHK-21 cells were transfected with the indicated HA-tagged CLRN1 plasmids. Nontransfected cells (0-BHK) were used as controls. Polypeptides were resolved on 12% SDS-PAGE, and anti-HA antibodies were used to probe the blots. Samples were untreated (-) or treated (+) with deglycosylating enzyme (PNGase F). The molecular weights of the protein bands are indicated on the left and right sides of the figure.
###end p 53
###begin title 54
Discussion
###end title 54
###begin p 55
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLRN1</italic>
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 272 277 272 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLRN1</italic>
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 470 478 <span type="species:ncbi:9606">patients</span>
###xml 582 589 <span type="species:ncbi:9606">patient</span>
###xml 705 712 <span type="species:ncbi:9606">patient</span>
A total of 13 CLRN1 mutations in more than 100 USH3 patients have been reported worldwide. The two most common single mutations are the founder mutations p.Y176X in the Finnish population, and the p.N48K mutation among Ashkenazi Jews [22,23,32]. The remaining 11 reported CLRN1 mutations occur in single, often consanguineous families, and are not known to be widely distributed. Therefore, it is not surprising that we found one p.N48K homozygote among 40 Canadian USH patients, and one compound p.Y176X/p.N48K heterozygote in Finland. The p.A123D mutation was found in a Canadian patient originating from Dominica. Interestingly, the same mutation has previously been reported in a French Canadian USH1 patient [34].
###end p 55
###begin p 56
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 288 289 288 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
###xml 237 244 <span type="species:ncbi:9606">patient</span>
###xml 320 327 <span type="species:ncbi:9606">patient</span>
###xml 351 358 <span type="species:ncbi:9606">patient</span>
###xml 405 412 <span type="species:ncbi:9606">patient</span>
Clinical studies of USH3 patients have failed to determine any clear-cut genotype-phenotype correlations while broad intrafamilial and mutational variety in the onset, progression, and severity of symptoms are reported among the largest patient groups, Ashkenazi Jews [11,32], and Finns [7,9,10]. The homozygous p.A123D patient, the homozygous p.N48K patient, and the combined heterozygous p.Y176X/p.N48K patient reported in this study had what can be considered typical USH3 phenotypes.
###end p 56
###begin p 57
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLRN1</italic>
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 675 676 675 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 677 679 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 680 682 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
The CLRN1 gene is predicted to encode a four-pass transmembrane domain protein [23]. Our results are in line with the previous observations that full-length WT CLRN1 is sorted to specific membrane compartments or to the cell surface [28,31]. Interestingly, molecular masses of the CLRN1-HA polypeptides observed on our western blots suggest that CLRN1 may form dimers and even higher order complexes. The function of the protein still remains unclear. The eight other known USH gene products are hypothesized to form an USH interactome with a role in the molecular transport in the photoreceptor connecting cilium, and in the development and function of cochlear hair cells [3,26-28]. The possible role of CLRN1 in the USH interactome, however, remains unclear.
###end p 57
###begin p 58
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLRN1</italic>
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r37">37</xref>
###xml 724 726 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r38">38</xref>
###xml 727 729 727 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r39">39</xref>
Half of the known CLRN1 mutations result in a premature termination codon and are likely to lead to nonfunctional proteins. Alternatively, the mutant mRNAs may be degraded by the nonsense-mediated decay pathway [37]. To assess pathogenic mechanisms of nontruncating mutations, we studied consequences of four missense mutations (p.N48K, p.M120K, p.A123D, and p.L150P), and that of the p.I153_L154delinsM mutation by expressing HA-tagged mutant cDNAs in BHK-21 cells. We showed that all the mutant CLRN1 proteins studied are retained in the ER and not trafficked to the plasma membrane. This is in line with the fact that missorting and mistrafficking of membrane proteins is a well-described mechanism of cell degeneration [38,39].
###end p 58
###begin p 59
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 826 828 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
###xml 829 831 829 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r41">41</xref>
###xml 1218 1223 1218 1223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Clrn1</italic>
###xml 1246 1248 1246 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r42">42</xref>
###xml 1231 1236 <span type="species:ncbi:10090">mouse</span>
We also studied the stability of WT and mutant proteins and found that all studied mutants were less stable than WT CLRN1-HA. The p.N48K, p.A123D and p.L150P mutants degraded more rapidly than p.M120K and p.I153_L154delinsM. A recent study with HEK-293 cells shows that disruption of glycosylation site by p.N48K mutation as well as removal of the N-linked sugar residue from the WT-CLRN1 both cause protein degradation, suggesting that the incorrect glycosylation is the cause for p.N48K mutated CLRN1 degradation [28]. Our study showed that mutations other than p.N48K are glycosylated, yet unstable. Therefore, it seems that glycosylation is not the sole determining factor for destabilization of mutated CLRN1 proteins in general. The accumulation of mutated proteins that cells inefficiently degrade may cause ER stress [40,41]. Retained as well as improperly processed mutant CLRN1 polypeptides are likely to cause ER stress, which in turn may trigger apoptosis in retinal and cochlear sensory epithelia. In a previous study, we showed that apoptosis is a probable pathogenic mechanism in USH3, as apoptotic cochlear cell destruction resulted from adeno-associated viral vectored ribozyme-initiated knockdown of Clrn1 in the mouse cochlea [42].
###end p 59
###begin p 60
In summary, our results showed that CLRN1 is a glycoprotein that forms multimers in plasma membranes of cultured cells. Further, we showed that instability and defective routing of mutant polypeptides are critical aspects of the etiology of USH3.
###end p 60
###begin title 61
Acknowledgments
###end title 61
###begin p 62
We thank Reetta Jalkanen for critical comments on the manuscript. This study was supported by De Blindas Vanner r.f., Finnish Eye and Tissue Bank Foundation, The Foundation Fighting Blindness, Hope for Vision, Retina Finland and The Research Foundation of the University of Helsinki. Portions of the data in this manuscript were presented as follows: at the 2005 Association for Research in Vision and Ophthalmology (ARVO) meeting in a poster presentation: Isosomppi J, Vastinsalo H, Geller SF, Flannery JG, Sankila EM, Cellular Localization and Processing of USH3A Protein Clarin-1 in Transiently Transfected Cell Lines; at the 2006 ARVO meeting in a poster presentation: Vastinsalo HM, Isosomppi J, Geller S, Flannery J, Heon E, Sankila EM, Functional Evaluation of Two Novel Ush3a Mutations by In Vitro Expression; and at the 2006 meeting of The International Society for Ocular Cell Biology (ISOCB) in a poster presentation: Isosomppi J, Vastinsalo H, Aittakorpi A, Geller SF, Heon E, Flannery JG, Sankila EM, Functional Evaluation of USH3A Protein Clarin-1 by In vitro Expression and Search for Clarin-1 Interacting Proteins.
###end p 62
###begin title 63
References
###end title 63
###begin article-title 64
Usher syndrome: from genetics to pathogenesis.
###end article-title 64
###begin article-title 65
The molecular genetics of Usher syndrome.
###end article-title 65
###begin article-title 66
###xml 19 24 <span type="species:ncbi:9606">human</span>
Molecular basis of human Usher syndrome: deciphering the meshes of the Usher protein network provides insights into the pathomechanisms of the Usher disease.
###end article-title 66
###begin article-title 67
Usher syndrome: molecular links of pathogenesis, proteins and pathways.
###end article-title 67
###begin article-title 68
Prevalence and geographical distribution of Usher syndrome in Germany.
###end article-title 68
###begin article-title 69
The changing face of Usher syndrome: clinical implications.
###end article-title 69
###begin article-title 70
###xml 85 93 <span type="species:ncbi:9606">patients</span>
Serial audiometry and speech recognition findings in Finnish Usher syndrome type III patients.
###end article-title 70
###begin article-title 71
Audiological and vestibular features in affected subjects with USH3: a genotype/phenotype correlation.
###end article-title 71
###begin article-title 72
The ophthalmological course of Usher syndrome type III.
###end article-title 72
###begin article-title 73
Visual impairment in Finnish Usher syndrome type III.
###end article-title 73
###begin article-title 74
Retinal disease in Usher syndrome III caused by mutations in the clarin-1 gene.
###end article-title 74
###begin article-title 75
Defective myosin VIIA gene responsible for Usher syndrome type 1B.
###end article-title 75
###begin article-title 76
del C-Salcedo Cabrera M, Vila MC, Molina OP, Gal A, Kubisch C. Mutation of CDH23, encoding a new member of the cadherin gene family, causes Usher syndrome type 1D.
###end article-title 76
###begin article-title 77
Mutations of the protocadherin gene PCDH15 cause Usher syndrome type 1F.
###end article-title 77
###begin article-title 78
Mutations in the novel protocadherin PCDH15 cause Usher syndrome type 1F.
###end article-title 78
###begin article-title 79
A defect in harmonin, a PDZ domain-containing protein expressed in the inner ear sensory hair cells, underlies Usher syndrome type 1C.
###end article-title 79
###begin article-title 80
Usher syndrome type I G (USH1G) is caused by mutations in the gene encoding SANS, a protein that associates with the USH1C protein, harmonin.
###end article-title 80
###begin article-title 81
A novel gene for Usher syndrome type 2: mutations in the long isoform of whirlin are associated with retinitis pigmentosa and sensorineural hearing loss.
###end article-title 81
###begin article-title 82
Mutations in the VLGR1 gene implicate G-protein signaling in the pathogenesis of Usher syndrome type II.
###end article-title 82
###begin article-title 83
Isolation of a gene encoding a novel member of the nuclear receptor superfamily from the critical region of Usher syndrome type IIa at 1q41.
###end article-title 83
###begin article-title 84
###xml 150 158 <span type="species:ncbi:9606">patients</span>
Identification of 51 novel exons of the Usher syndrome type 2A (USH2A) gene that encode multiple conserved functional domains and that are mutated in patients with Usher syndrome type II.
###end article-title 84
###begin article-title 85
Mutations in a novel gene with transmembrane domains underlie Usher syndrome type 3.
###end article-title 85
###begin article-title 86
USH3A transcripts encode clarin-1, a four-transmembrane-domain protein with a possible role in sensory synapses.
###end article-title 86
###begin article-title 87
Usher I syndrome: unravelling the mechanisms that underlie the cohesion of the growing hair bundle in inner ear sensory cells.
###end article-title 87
###begin article-title 88
Scaffold protein harmonin (USH1C) provides molecular links between Usher syndrome type 1 and type 2.
###end article-title 88
###begin article-title 89
Interactions in the network of Usher syndrome type 1 proteins.
###end article-title 89
###begin article-title 90
A novel Usher protein network at the periciliary reloading point between molecular transport machineries in vertebrate photoreceptor cells.
###end article-title 90
###begin article-title 91
Clarin-1, encoded by the Usher syndrome III causative gene, forms a membranous microdomain: possible role of clarin-1 in organizing the actin cytoskeleton.
###end article-title 91
###begin article-title 92
Usher syndrome type III: revised genomic structure of the USH3 gene and identification of novel mutations.
###end article-title 92
###begin article-title 93
Usher syndrome IIIA gene clarin-1 is essential for hair cell function and associated neural activation.
###end article-title 93
###begin article-title 94
Localization and expression of clarin-1, the Clrn1 gene product, in auditory hair cells and photoreceptors.
###end article-title 94
###begin article-title 95
Genetic homogeneity and phenotypic variability among Ashkenazi Jews with Usher syndrome type III.
###end article-title 95
###begin article-title 96
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Mutation screening of USH3 gene (clarin-1) in Spanish patients with Usher syndrome: low prevalence and phenotypic variability.
###end article-title 96
###begin article-title 97
###xml 85 90 85 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USH1C</italic>
Deafblindness in French Canadians from Quebec: a predominant founder mutation in the USH1C gene provides the first genetic link with the Acadian population.
###end article-title 97
###begin article-title 98
The sequence manipulation suite: JavaScript programs for analyzing and formatting protein and DNA sequences.
###end article-title 98
###begin article-title 99
Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes.
###end article-title 99
###begin article-title 100
Nonsense-mediated mRNA decay modulates clinical outcome of genetic disease.
###end article-title 100
###begin article-title 101
Transport of truncated rhodopsin and its effects on rod function and degeneration.
###end article-title 101
###begin article-title 102
###xml 86 89 <span type="species:ncbi:10116">rat</span>
Characterization of rhodopsin mis-sorting and constitutive activation in a transgenic rat model of retinitis pigmentosa.
###end article-title 102
###begin article-title 103
Endoplasmic reticulum stress in disease pathogenesis.
###end article-title 103
###begin article-title 104
Disease-related misassembly of membrane proteins.
###end article-title 104
###begin article-title 105
###xml 62 67 <span type="species:ncbi:10090">mouse</span>
Anti-clarin-1 AAV-delivered ribozyme induced apoptosis in the mouse cochlea.
###end article-title 105

